925 related articles for article (PubMed ID: 27207971)
41. Edoxaban: a review in nonvalvular atrial fibrillation.
McCormack PL
Am J Cardiovasc Drugs; 2015 Oct; 15(5):351-61. PubMed ID: 26369340
[TBL] [Abstract][Full Text] [Related]
42. Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction).
Aisenberg J; Chatterjee-Murphy P; Friedman Flack K; Weitz JI; Ruff CT; Nordio F; Mercuri MF; Choi Y; Antman EM; Braunwald E; Giugliano RP
Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e003998. PubMed ID: 29748353
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Halperin JL; Hankey GJ; Wojdyla DM; Piccini JP; Lokhnygina Y; Patel MR; Breithardt G; Singer DE; Becker RC; Hacke W; Paolini JF; Nessel CC; Mahaffey KW; Califf RM; Fox KA;
Circulation; 2014 Jul; 130(2):138-46. PubMed ID: 24895454
[TBL] [Abstract][Full Text] [Related]
44. Laboratory Test Predictors for Major Bleeding in Elderly (≥80 Years) Patients With Nonvalvular Atrial Fibrillation Treated With Edoxaban 15 mg: Sub-Analysis of the ELDERCARE-AF Trial.
Mikami T; Hirabayashi K; Okawa K; Betsuyaku T; Watanabe S; Imamura Y; Tanizawa K; Hayashi T; Akao M; Yamashita T; Okumura K
J Am Heart Assoc; 2022 Sep; 11(17):e024970. PubMed ID: 36056729
[TBL] [Abstract][Full Text] [Related]
45. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.
Kimachi M; Furukawa TA; Kimachi K; Goto Y; Fukuma S; Fukuhara S
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011373. PubMed ID: 29105079
[TBL] [Abstract][Full Text] [Related]
46. First experience with edoxaban and atrial fibrillation ablation - Insights from the ENGAGE AF-TIMI 48 trial.
Steffel J; Ruff CT; Hamershock RA; Murphy SA; Senior R; Roy D; Lanz HJ; Mercuri MF; Antman EM; Giugliano RP
Int J Cardiol; 2017 Oct; 244():192-195. PubMed ID: 28625512
[TBL] [Abstract][Full Text] [Related]
47. Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial.
Yin OQP; Antman EM; Braunwald E; Mercuri MF; Miller R; Morrow D; Ruff CT; Truitt K; Weitz JI; Giugliano RP
Circulation; 2018 Oct; 138(18):1963-1973. PubMed ID: 29967197
[TBL] [Abstract][Full Text] [Related]
48. Impact of Renal Function on Outcomes With Edoxaban in Real-World Patients With Atrial Fibrillation.
Yu HT; Yang PS; Kim TH; Jang E; Kim D; Uhm JS; Kim JY; Pak HN; Lee MH; Lip GYH; Joung B
Stroke; 2018 Oct; 49(10):2421-2429. PubMed ID: 30355093
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis.
Savarese G; Giugliano RP; Rosano GM; McMurray J; Magnani G; Filippatos G; Dellegrottaglie S; Lund LH; Trimarco B; Perrone-Filardi P
JACC Heart Fail; 2016 Nov; 4(11):870-880. PubMed ID: 27614940
[TBL] [Abstract][Full Text] [Related]
50. Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation.
Okumura K; Akao M; Yoshida T; Kawata M; Okazaki O; Akashi S; Eshima K; Tanizawa K; Fukuzawa M; Hayashi T; Akishita M; Lip GYH; Yamashita T;
N Engl J Med; 2020 Oct; 383(18):1735-1745. PubMed ID: 32865374
[TBL] [Abstract][Full Text] [Related]
51. A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
Lip GY; Merino J; Ezekowitz M; Ellenbogen K; Zamoryakhin D; Lanz H; Jin J; Al-Saadi N; Mercuri M; Goette A
Am Heart J; 2015 May; 169(5):597-604.e5. PubMed ID: 25965706
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and Safety of Edoxaban in Nonvalvular Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials.
Chen J; Zhuang X; Long M; Su C; Wang L
J Stroke Cerebrovasc Dis; 2015 Dec; 24(12):2710-9. PubMed ID: 26324517
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial.
Nicolau AM; Corbalan R; Nicolau JC; Ruff CT; Zierhut W; Kerschnitzki M; Duris T; Juul-Möller S; Voitk J; Trevisan M; Nordio F; Antman EM; Giugliano RP
Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(3):167-175. PubMed ID: 31687762
[TBL] [Abstract][Full Text] [Related]
54. Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial.
Douketis JD; Murphy SA; Antman EM; Grip LT; Mercuri MF; Ruff CT; Weitz JI; Braunwald E; Giugliano RP
Thromb Haemost; 2018 Jun; 118(6):1001-1008. PubMed ID: 29723874
[TBL] [Abstract][Full Text] [Related]
55. A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial.
Fanola CL; Giugliano RP; Ruff CT; Trevisan M; Nordio F; Mercuri MF; Antman EM; Braunwald E
Eur Heart J; 2017 Mar; 38(12):888-896. PubMed ID: 28064150
[TBL] [Abstract][Full Text] [Related]
56. Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial.
Steffel J; Giugliano RP; Braunwald E; Murphy SA; Atar D; Heidbuchel H; Camm AJ; Antman EM; Ruff CT
Eur Heart J; 2015 Sep; 36(33):2239-45. PubMed ID: 25971288
[TBL] [Abstract][Full Text] [Related]
57. Edoxaban in Asian Patients With Atrial Fibrillation: Effectiveness and Safety.
Lee SR; Choi EK; Han KD; Jung JH; Oh S; Lip GYH
J Am Coll Cardiol; 2018 Aug; 72(8):838-853. PubMed ID: 30115222
[TBL] [Abstract][Full Text] [Related]
58. Cost-Effectiveness of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation Based on Results of the ENGAGE AF - TIMI 48 Trial: Taiwanese Perspective.
Vilain KA; Yang MC; Hui Tan EC; Wang K; Li H; Hsu WH; Giugliano RP; Cohen DJ; Magnuson EA;
Value Health Reg Issues; 2017 May; 12():74-83. PubMed ID: 28648320
[TBL] [Abstract][Full Text] [Related]
59. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Deng Y; Tong Y; Deng Y; Zou L; Li S; Chen H
J Am Heart Assoc; 2019 Jul; 8(14):e012540. PubMed ID: 31310583
[TBL] [Abstract][Full Text] [Related]
60. Outcomes and Safety of Very-Low-Dose Edoxaban in Frail Patients With Atrial Fibrillation in the ELDERCARE-AF Randomized Clinical Trial.
Akashi S; Oguri M; Ikeno E; Manita M; Taura J; Watanabe S; Hayashi T; Akao M; Okumura K; Akishita M; Yamashita T
JAMA Netw Open; 2022 Aug; 5(8):e2228500. PubMed ID: 35997978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
